Journal
JOURNAL OF HEPATOLOGY
Volume 65, Issue 5, Pages 1031-1042Publisher
ELSEVIER
DOI: 10.1016/j.jhep.2016.05.035
Keywords
Liver cancer; Deep sequencing; Mutation; Genomics; Signature
Categories
Funding
- American Association for the Study of Liver Diseases Foundation Alan Hofmann Clinical and Translational Research Award
Ask authors/readers for more resources
Hepatocellular carcinoma (HCC) is a highly heterogeneous disease, both clinically and from a molecular standpoint. The advent of next-generation sequencing technologies has provided new opportunities to extensively analyze molecular defects in HCC samples. This has uncovered major cancer driver genes and associated oncogenic pathways operating in HCC. More sophisticated analyses of sequencing data have linked specific nucleotide patterns to external toxic agents and defined so-called 'mutational signatures' in HCC. Molecular signatures, taking into account intra- and inter-tumor heterogeneity, and their functional validation could provide useful data to predict treatment response to molecular therapies. In this review we will focus on the current knowledge of deep sequencing in HCC and its foreseeable clinical impact. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available